Introduction
Development of epithelial malignancy is regulated by the immune system, as chronic immunosuppression after organ transplantation is associated with a greatly increased risk of squamous cancer. Many cancers of epithelial origin express tumour specific modified self proteins as neo-self antigens (Buckwalter and Srivastava, 2008) . Epithelial cancer can also arise from skin persistently infected with virus, including human papillomavirus (Al-Daraji and Smith, 2009 ) and Merkel tumour associated retrovirus (Feng et al., 2008) , and these tumours continue to express virus encoded antigen. Evidently, neoself or viral antigens expressed in squamous epithelial cancer fail to induce an immune response adequate to eliminate the cancer. Better understanding of the requirement for effective immune mediated elimination of keratinocytes expressing viral or neo self antigen would therefore assist in the design of appropriate immunotherapeutic interventions for squamous epithelial cancer.
We have developed a murine model to study the requirements for effective immunotherapy directed at antigen expressed in keratinocytes. Skin expressing a non-self or neo-antigen as a transgene in keratinocytes from a keratin promoter is grafted to a syngeneic non transgenic recipient . This allows us to study the requirements for inducing and delivering an effective immune response to antigen expressed only in keratinocytes, and not directly presented to the immune system by professional antigen presenting cells(APC).
The fate of a graft of skin expressing non self antigen in keratinocytes depends on the antigen. Some antigens including papillomavirus nonstructural proteins fail to invoke spontaneous rejection of grafts (Dunn et al., 1997) , allowing study of the requirements for effective induction of immunity after antigen cross presentation from keratinocytes. Other antigens, including ovalbumin (Holcmann et al., 2009 ) and human growth hormone , which is closely related in sequence to mouse growth hormone and therefore a neo-self antigen in the mouse, induce spontaneous graft rejection, allowing study of elimination of keratinocytes by primed T cells in a second graft following immune mediated elimination of a priming graft.
To prime a cytotoxic CD8 effector T cell response from naïve antigen specific Recent in vitro evidence suggests however that CD4 T cells can assist in secondary responses to cross-presented but not directly presented antigen (Blachere et al., 2006) . We have also previously shown a requirement for CD4 cells in a secondary immune response to human growth hormone in FVB mice of H-2q x H-2b genetic background (Zhong et al., 2008) . To extend this observation to mice of a genetic background more commonly used for studies of immune physiology and therefore enable further dissection of the mechanisms by which CD4 cells contribute to elimination of keratinocytes following priming or immunisation, we created K14.hGH transgenic mice on a C57/Bl6 genetic background. We evaluated the role of CD4 T cells in rejection of epithelial cells expressing various non-self antigens using these mice. Here we present data showing that CD4 T cell help improves the efficacy of rejection by already primed CD8 effector T cells of skin expressing either non self antigen or neo-self antigen in keratinocytes, and demonstrate that the requirement for CD4 cell responses can be substituted by CD40 costimulation.
Results

Second-set syngeneic skin grafts expressing hGH as a neo-self antigen are more rapidly rejected by C57Bl/6 recipients than the primary graft
We grafted skin expressing antigen as a transgene in keratinocytes to naïve C57Bl/6 (C57) recipient animals, and measured time to graft rejection to assess the immune response induced to the expressed antigen. We first studied recall responses to human growth hormone (hGH), a near homologue of mouse growth hormone representing modified self (neo-self). Animals that rejected a hGH transgenic graft were considered primed to hGH, and received a further hGH graft. Primary hGH grafts on C57 mice were rejected in a median of 31.5 days (Fig. 1A) , as was observed for C57 x FVB mice and in contrast to the findings for FVB mice, which rarely reject primary hGH grafts . Second hGH grafts placed on graft primed C57 recipients were rejected with a median survival time of 21 days, significantly earlier than the initial graft (p=0.018). The recall response to hGH by C57 mice is consistent with observations for FVB x C57 mice .
Rejection of second-set hGH skin grafts requires CD4 cells
Rejection by FVB x C57 mice of skin expressing hGH antigen in keratinocytes requires both CD4 and CD8 T cells Zhong et al., 2008) . To establish, for C57 mice, whether CD4 T cells are required for rejection of hGH transgenic skin following priming, hGH graft primed C57 animals were depleted of CD4 T cells, and given a second hGH graft ( Fig   1B) . Rejection of second hGH grafts occurred in 8% (1/13) of CD4 depleted recipients, compared with 87% (7/8) of CD4 replete recipients (p<0.0001).
Thus, CD4 T cells are important not only for priming but also for optimal rejection by CD8 T cells of hGH grafts from an hGH graft primed C57animal. 
CD4 T cells alone are not sufficient for graft rejection
To establish whether CD4 T cells alone could effect rejection of a K5.mOVA graft, 2.5x10 7 OT-II spleen cells, specific for a CD4 restricted epitope of OVA,
were transferred into Rag1 -/-recipients(n=16), which 3 days later received a K5.mOVA skin graft. FACS staining of peripheral blood on the day of grafting confirmed successful transfer of CD4 T cells (Fig 4) . K5.mOVA grafts (13/16) were generally accepted by immunodeficient Rag 1 -/-animals whether or not they received OVA specific CD4 OT-II T cells (p=0.37; Fig. 4 ), in contrast to the findings for OVA specific CD8 T cells described above. Thus OVA specific CD4 T cells are unable, in the absence of OVA specific CD8 cytotoxic T cells, to reject OVA expressing skin grafts.
The number of transferred Rag-OT-I spleen cells determines the rate of
K5mOVA graft rejection
As CD4 T cells are necessary for rejection of skin expressing hGH but not OVA from naïve and antigen primed animals, and are insufficient to achieve rejection of skin grafts without CD8 T cells, we investigated whether CD4 T cells might accelerate CD8 T cell-mediated K5.mOVA skin graft rejection.
OT-I OVA specific CD8 cytotoxic T cells (10 6 ) were transferred with or without OT-II OVA specific CD4 helper T cells (10 6 ) to immunodeficient recipient were transferred with or without 10 6 OVA specific OT-II CD4 T cells (Fig. 5C ).
K5.mOVA skin grafts were rejected from recipients of OVA specific CD8 spleen cells alone with a median survival time of 40 days. When both OVA specific CD8 and OVA specific CD4 T cells were transferred, median graft survival time was significantly shorter at 16 days (p=0.022). Thus in animals with physiological precursor frequencies of antigen specific CD8 T cells of 100-1000 (Lammermann and Sixt, 2008) antigen specific CD4 T cells enhance skin graft rejection.
CD4 T cell help for memory CD8 T cells.
OVA specific CD4 T cells might enhance OVA graft rejection by OVA specific CD8 cells in the previously described experiments by assisting with the priming of naïve OVA specific CD8 T cells. 
Materials and Methods
Mice
All experimental protocols were approved by the animal ethics committee of the University of Queensland. Mice were maintained under conventional conditions in specific pathogen-free holding rooms in the Princess Alexandra
Hospital Biological Resources Facility, University of Queensland.
Transgenic mice used in these studies are detailed in Table 1 . OT-II and 
Skin grafting
Whole-thickness ear skin grafting was performed as previously described (Frazer et al., 1998) . Grafts were examined every second day and were classified as rejected if there was >80% loss of epithelium, and as accepted if there was no rejection by day 50. Rejection or acceptance of transgenic skin was confirmed genetically and histologically in a random sample of mice. Where repeat grafting was undertaken it was performed on the opposite flank. Antibody was administered according to a published schedule (Fischbein et al., 2000) shown effective in our laboratory .
CD4 cell depletion
Preparation and transfer of spleen cells
A single cell suspension of spleen cells in DMEM (Invitrogen) was prepared. 
In vitro activation of OT-1 T cells
OT-I T cells were in vitro activated as described by Kenna et al (Kenna et al., 2008) . Briefly, OT-I lymph node cells were harvested and cultured in complete RPMI (RPMI 1640 supplemented with 1mM sodium pyruvate, 0.1mM nonessential amino acids, 50μM 2-ME) with 1% normal mouse serum, 0.1μg/mL OVA 257-264 and 10ng/mL interleukin-2. After 3 days, cells were harvested and washed (3x) with RPMI 1640 and re-cultured in 6-well plates at depleted C57Bl/6 recipient animals (n=12). Survival differences were assessed for significance using log-rank (Mantel-Cox) test. ) were administered with (n=4) or without ( n=4) OVA specific T helper (OT-II) spleen cells (10 6 ) to immunodeficient Rag1-/-recipients. After 3 days, K5mOVA skin grafts were placed and followed to rejection. C, Rag -/-2C immunodeficient mice received 10 2 OVA specific CD8
OT-1 cells , or 10 2 OT-1 cells and 10 6 OVA specific CD4 OT-2 cells.
K5.mOVA skin grafts were placed and followed to rejection. Graft survival over time is shown. Survival differences were assessed for significance using log-rank (Mantel-Cox) test. Results are from two separate experiments. K5.mOVa skin grafts were placed and followed to rejection. Graft survival over time is shown. Survival differences were assessed for significance using logrank (Mantel-Cox) test.
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